High-dose busulfan is a major risk factor for ovarian dysfunction in girls after stem cell transplantation

Clinical Pediatric Endocrinology

Volumn 12, Issue 1, 2003, Pages 13-18

  Maeda, Naoko ^a   Kato, Koji ^a   Matsuyama, Takaharu ^a   Kojima, Seiji ^b   Ohyama, Kenji ^c  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Busulfan; Menstruation; Ovarian dysfunction; Puberty; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MELPHALAN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AMENORRHEA; APLASTIC ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EVALUATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOMA; MENSTRUATION; OVARY DISEASE; RISK FACTOR; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 22744449038     PISSN: 09185739     EISSN: 13477358     Source Type: Journal    
DOI: 10.1297/cpe.12.13     Document Type: Article

References (23)

1. Spinelli S, Chiodi S, Bacigalupo A, Brasca A, Menada MV, Petti AR, et al. Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: long-term follow up of 79 females. Bone Marrow Transplant 1994;14:373-80.
2. Sanders JE, Buckner CD, Amos D, Levy W, Appelbaum FR, Doney K, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988;6:813-8.
3. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-52.
4. Dopfer R, Ranke M, Blum W, Ehninger G, Niethammer D. Influence of allogeneic bone marrow transplantation on the endocrine system in children. Transplant Proc 1989;21:3070-3.
5. Clement-De Boers A, Oostdijk W, Van Weel-Sipman MH, Van den Broeck J, Wit JM, Vossen JM. Final height and hormonal function after bone marrow transplantation in children. J Pediatr 1996;129:544-50.
6. Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr 1997;130:210-6.
7. Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998;21:287-90.
8. Mertens AC, Ramsay NK, Kouris S, Neglia JP. Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transplant 1998;22:345-50.
9. Matsumoto M, Shinohara O, Ishiguro H, Shimizu T, Hattori K, Ichikawa M, et al. Ovarian function after bone marrow transplantation performed before menarche. Arch Dis Child 1999;80:452-4.
10. Sklar C, Boulad F, Small T, Kernan N. Endocrine complications of pediatric stem cell transplantation. Front Biosci 2001;6:G17-22.
11. Matsuyama T, Kojima S, Kato K. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan regimen. Bone Marrow Transplant 1998;22:21-6.
12. Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998;22:989-94.
13. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976;37 (2 Suppl):1111-25.
14. Siris ES, Leventhal BG, Vaitukaitis JL. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976;242:1143-6.
15. Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril 1986;45:443-59.
16. Thibaud E, Ramirez M, Brauner R, Flamant F, Zucker JM, Fekete C, Rappaport R. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr 1992;121:880-4.
17. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980;53:271-8.
18. Janson PO, Jansson I, Skryten A, Dambler J, Lindstedt G. Ovarian endocrine function in young women undergoing radiotherapy for carcinoma of the cervix. Gynecol Oncol 1981;11:218-23.
19. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1 (8230):1132-4.
20. Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;45:3651-6.
21. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72.
22. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997;29:199-206.
23. Pereyra Pacheco B, Mendez Ribas JM, Milone G, Fernandez I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7.